The core technology comprises targeted lipid nanoparticles (tLNPs) to enable engineering or ablation of pathogenic cells in the body. Potential treatment options include oncology, fibrosis, inflammation-related diseases, and monogenic blood disorders.

In September 2022, the company received $165 million in financing to develop its foundational precision in vivo engineering technology.